Ambry Genetics

03/27/2026

We are headed to Cleveland for the 2026 NCoBC Annual Meeting. Visit us at booth 200+201 to learn more about Ambry's hereditary cancer testing and The Ambry CARE Program®. Check out our presentations or schedule a meeting at https://hubs.ly/Q046WCBL0

03/25/2026

Danielle Rogers is an oncology and genetics nurse practitioner who serves as a genetic counseling resource for patients from a variety of clinics in Florida. She recently shared some of her experiences. Hear how personalized cancer risk assessments improved after the implementation of the Ambry CARE Program®.
https://hubs.ly/Q0482LlK0

03/24/2026

Need help making sense of how sequencing approaches in hereditary cancer have evolved and where they are heading? Our new review article breaks down the strengths and future directions of these technologies to help clinicians and researchers stay informed.
https://hubs.ly/Q0486tTx0

03/24/2026

Each week, we explore a gene from the ACMG Secondary Findings list. This week, join Rachel Bluebond, MMSc, CGC, as she explores SMAD4 and its associated conditions of juvenile polyposis syndrome (JPS) and Myhre syndrome. Dive deeper: https://hubs.ly/Q0482MJD0

03/22/2026

Noelle Carbognin has a message for . Passionate about precision medicine and patient advocacy, she is not only knowledgeable about the difference Ambry's genetic tests can make, but she has lived it. Listen to part of her previvor story that she shared on Doctor Radio.

03/20/2026

Ambry Genetics is proud to share newly published data describing duoNovo, a tool that uses long‑read sequencing to identify de novo variants from parent–proband duos—expanding diagnostic options when only one parent is available. This work, produced in collaboration with the GREGoR consortium, promises to improve equity and access to genetic diagnosis for families who previously lacked both‑parent sequencing.
https://hubs.ly/Q047lGNk0

03/19/2026

Smarter screening and prevention start with risk insights. Don’t miss these opportunities at to learn more about how the Ambry CARE Program® helps centers strengthen high-risk patient identification. https://hubs.ly/Q0477hDg0

03/19/2026

03/18/2026

Join us for a webinar on Wednesday, March 25, at 10 am PDT.
Explore the current landscape of genomic literacy and discuss practical strategies for improving understanding across the communities most impacted by these technologies.
https://hubs.ly/Q046WGZK0

03/17/2026

We’re excited to share that Ambry’s hereditary cancer testing turnaround times are faster than ever before, helping you make timely, confident decisions for your patients.

Our BRCAplus® STAT test now delivers results in just 4–7 days, providing rapid insights when time matters most. In addition, our other hereditary cancer panels now have a 5–14 day turnaround time, offering both speed and comprehensive coverage across indications.

Learn more: https://hubs.ly/Q046WpNl0

03/17/2026

Haaniya Mallick, MS, CGC, joins us for The Gene Scene where we explore the clinical recommendations for a gene from the ACMG Secondary Findings list. This week, she breaks down CASQ2 and its link to CASQ2-related catecholaminergic polymorphic ventricular tachycardia (CPVT). https://hubs.ly/Q046Wr7k0

03/16/2026

ICYMI: Join Ambry experts and from to get the recap on with industry insights into whole genome sequencing, AI, and more!

See how tools like long read sequencing, RNA sequencing, MAVEs, and AI are ethically transforming WGS to make patients lives better.